Charles River Laboratories International Croissance future
Future contrôle des critères 1/6
Charles River Laboratories International devrait augmenter ses bénéfices et son chiffre d'affaires de 11.7% et de 4.4% par an respectivement. Le BPA devrait croître de de 12.3% par an. Le rendement des capitaux propres devrait être 11.9% dans 3 ans.
Informations clés
11.7%
Taux de croissance des bénéfices
12.3%
Taux de croissance du BPA
| Life Sciences croissance des bénéfices | 18.3% |
| Taux de croissance des recettes | 4.4% |
| Rendement futur des capitaux propres | 11.9% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 18 Nov 2024 |
Mises à jour récentes de la croissance future
Recent updates
Charles River Laboratories: Not The Right Time To Own At This Point In The Cycle
Nov 19Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 26
What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You
Oct 11Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching
Sep 10US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results
Aug 10Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Aug 10Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt
Jul 26Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)
Jul 11Charles River Laboratories: Fair Valuation Against Fundamentals
May 31What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?
May 25Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?
Apr 27Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 4,367 | 441 | 431 | 768 | 15 |
| 12/31/2025 | 4,105 | 341 | 379 | 684 | 17 |
| 12/31/2024 | 4,030 | 301 | 373 | 579 | 16 |
| 9/28/2024 | 4,061 | 413 | 560 | 796 | N/A |
| 6/29/2024 | 4,078 | 432 | 487 | 750 | N/A |
| 3/30/2024 | 4,112 | 439 | 414 | 704 | N/A |
| 12/30/2023 | 4,129 | 475 | 365 | 684 | N/A |
| 9/30/2023 | 4,216 | 475 | 368 | 698 | N/A |
| 7/1/2023 | 4,178 | 484 | 289 | 625 | N/A |
| 4/1/2023 | 4,092 | 496 | 275 | 626 | N/A |
| 12/31/2022 | 3,976 | 486 | 295 | 620 | N/A |
| 9/24/2022 | 3,781 | 436 | 280 | 614 | N/A |
| 6/25/2022 | 3,688 | 443 | 338 | 656 | N/A |
| 3/26/2022 | 3,630 | 422 | 412 | 693 | N/A |
| 12/25/2021 | 3,540 | 391 | 532 | 761 | N/A |
| 9/25/2021 | 3,426 | 397 | 452 | 670 | N/A |
| 6/26/2021 | 3,273 | 396 | 484 | 672 | N/A |
| 3/27/2021 | 3,041 | 375 | 479 | 648 | N/A |
| 12/26/2020 | 2,924 | 364 | 380 | 547 | N/A |
| 9/26/2020 | 2,824 | 301 | 446 | 589 | N/A |
| 6/27/2020 | 2,749 | 271 | 416 | 567 | N/A |
| 3/28/2020 | 2,724 | 248 | 385 | 535 | N/A |
| 12/28/2019 | 2,621 | 252 | 340 | 481 | N/A |
| 9/28/2019 | 2,532 | 231 | 295 | 440 | N/A |
| 6/29/2019 | 2,449 | 219 | 269 | 402 | N/A |
| 3/30/2019 | 2,377 | 227 | 264 | 393 | N/A |
| 12/29/2018 | 2,266 | 225 | 297 | 437 | N/A |
| 9/29/2018 | 2,143 | 135 | 321 | 421 | N/A |
| 6/30/2018 | 2,022 | 128 | N/A | 363 | N/A |
| 3/31/2018 | 1,906 | 129 | N/A | 342 | N/A |
| 12/30/2017 | 1,858 | 123 | N/A | 316 | N/A |
| 9/30/2017 | 1,846 | 198 | N/A | 310 | N/A |
| 7/1/2017 | 1,807 | 183 | N/A | 323 | N/A |
| 4/1/2017 | 1,772 | 164 | N/A | 303 | N/A |
| 12/31/2016 | 1,681 | 154 | N/A | 315 | N/A |
| 9/24/2016 | 1,568 | 143 | N/A | 299 | N/A |
| 6/25/2016 | 1,492 | 143 | N/A | 315 | N/A |
| 3/26/2016 | 1,398 | 156 | N/A | 321 | N/A |
| 12/26/2015 | 1,363 | 150 | N/A | 305 | N/A |
| 9/26/2015 | 1,339 | 146 | N/A | 284 | N/A |
| 6/27/2015 | 1,317 | 140 | N/A | 263 | N/A |
| 3/28/2015 | 1,319 | 127 | N/A | 234 | N/A |
| 12/27/2014 | 1,298 | 128 | N/A | 251 | N/A |
| 9/27/2014 | 1,257 | 120 | N/A | 214 | N/A |
| 6/28/2014 | 1,222 | 119 | N/A | 214 | N/A |
| 3/29/2014 | 1,174 | 111 | N/A | 205 | N/A |
| 12/28/2013 | 1,166 | 104 | N/A | 207 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de CRL ( 11.7% par an) est supérieure au taux d'épargne ( 2.6% ).
Bénéfices vs marché: Les bénéfices de CRL ( 11.7% par an) devraient croître plus lentement que le marché US ( 15.4% par an).
Croissance élevée des bénéfices: Les bénéfices de CRL devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de CRL ( 4.4% par an) devrait croître plus lentement que le marché de US ( 9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de CRL ( 4.4% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de CRL devrait être faible dans 3 ans ( 11.9 %).